Search research articles
Contact Us
Filters
Showing results (21-30 of 33) with videos related to
Page
of 4
Sort By:
Hepatology (Baltimore, Md.)
|
July 17, 2024
Reply: The causal analysis of missing confounding factors for the association between HDV and specific liver events
Robert G Gish, Robert J Wong, Gian Luca Di Tanna, et al.
Leukemia & Lymphoma
|
December 8, 2025
Short-term costs associated with outpatient use of axicabtagene ciloleucel in second-line and above relapsed/refractory large B-cell lymphoma based on the zuma-24 clinical trial
Olalekan O Oluwole, Sally W Wade, Nathaniel J Smith, et al.
Hepatology (Baltimore, Md.)
|
October 23, 2023
Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis
Robert G Gish, Robert J Wong, Gian Luca Di Tanna, et al.
Journal of Medical Economics
|
December 6, 2023
An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States
Olalekan O Oluwole, Anik R Patel, Sachin Vadgama, et al.
Journal of Medical Economics
|
September 27, 2023
The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population
Derek Ebner, John Kisiel, Lianne Barnieh, et al.
Advances in Therapy
|
June 21, 2022
Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States
Bijal D Shah, Nathaniel J Smith, Chaoling Feng, et al.
Population Health Management
|
December 27, 2021
Cost-Effectiveness of Outreach Strategies for Stool-Based Colorectal Cancer Screening in a Medicaid Population
Jordan J Karlitz, A Mark Fendrick, Jay Bhatt, et al.
Transplantation and Cellular Therapy
|
August 15, 2022
The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial
Miguel-Angel Perales, John Kuruvilla, Julia Thornton Snider, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
June 24, 2016
Dopamine D3 Receptor Availability Is Associated with Inflexible Decision Making
Stephanie M Groman, Nathaniel J Smith, J Ryan Petrullli, et al.
Transplantation and Cellular Therapy
|
September 10, 2025
Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed/Refractory Large B-cell Lymphoma
Miguel-Angel Perales, Olalekan O Oluwole, Anik R Patel, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 33) with videos related to
Sort By:
Page
of 4
Hepatology (Baltimore, Md.)
|
July 17, 2024
Reply: The causal analysis of missing confounding factors for the association between HDV and specific liver events
Robert G Gish, Robert J Wong, Gian Luca Di Tanna, et al.
Leukemia & Lymphoma
|
December 8, 2025
Short-term costs associated with outpatient use of axicabtagene ciloleucel in second-line and above relapsed/refractory large B-cell lymphoma based on the zuma-24 clinical trial
Olalekan O Oluwole, Sally W Wade, Nathaniel J Smith, et al.
Hepatology (Baltimore, Md.)
|
October 23, 2023
Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis
Robert G Gish, Robert J Wong, Gian Luca Di Tanna, et al.
Journal of Medical Economics
|
December 6, 2023
An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States
Olalekan O Oluwole, Anik R Patel, Sachin Vadgama, et al.
Journal of Medical Economics
|
September 27, 2023
The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population
Derek Ebner, John Kisiel, Lianne Barnieh, et al.
Advances in Therapy
|
June 21, 2022
Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States
Bijal D Shah, Nathaniel J Smith, Chaoling Feng, et al.
Population Health Management
|
December 27, 2021
Cost-Effectiveness of Outreach Strategies for Stool-Based Colorectal Cancer Screening in a Medicaid Population
Jordan J Karlitz, A Mark Fendrick, Jay Bhatt, et al.
Transplantation and Cellular Therapy
|
August 15, 2022
The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial
Miguel-Angel Perales, John Kuruvilla, Julia Thornton Snider, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
June 24, 2016
Dopamine D3 Receptor Availability Is Associated with Inflexible Decision Making
Stephanie M Groman, Nathaniel J Smith, J Ryan Petrullli, et al.
Transplantation and Cellular Therapy
|
September 10, 2025
Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed/Refractory Large B-cell Lymphoma
Miguel-Angel Perales, Olalekan O Oluwole, Anik R Patel, et al.
Page
of 4